Rifampin Capsules recalled due to excess nitrosamine impurity
Golden State Medical Supply Inc. is recalling Rifampin Capsules, 150 mg, due to elevated levels of 1-Methyl-4-Nitrosopiperazine (MNP) exceeding the FDA interim specification limit of 5 ppm. Affected lots are distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II drug recall for a quality specification failure. No illnesses or injuries have been reported. The hazard is an elevated impurity level rather than an immediate safety threat, consistent with precautionary recalls.
Plain-English summary
Golden State Medical Supply Inc. is recalling Rifampin Capsules, USP, 150 mg, 30-count bottles. The recall affects specific lots with expiration dates ranging from October 31, 2022, through February 29, 2024. The product was manufactured by Patheon Pharmaceuticals Inc. in Ohio and packaged by GSMS, Incorporated in California.
The recall was initiated because the finished product exceeds the FDA interim specification limit of 5 ppm for 1-Methyl-4-Nitrosopiperazine (MNP), a degradation impurity. This represents a failure to meet established quality standards.
The affected lots have been distributed throughout the United States. Patients currently taking Rifampin from these lots should contact their healthcare provider or pharmacist before making any changes to their medication regimen.
The recalled product
- Product
- Rifampin Capsules, USP, 150 mg, 30-count bottle, Rx only, Manufactured by Patheon Pharmaceuticals Inc., OH, Packaged by GSMS, Incorporated, CA, NDC 51407-322-30
- Manufacturer
- Golden State Medical Supply Inc.
- Category
- Drug — Prescription / Antibiotic
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (19)
- Lot #: GS036715
- GS037569
- GS038132
- GS038665
- GS038750
- GS039565
- GS039997
- GS040673
- Exp 10/31/2022
- GS040674
- GS041237
- GS041652
- GS042152
- GS043365
- Exp 3/31/2023
- GS045441
- GS045677
- GS046111
- Exp 2/29/2024.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Golden State Medical Supply Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · Golden State Medical Supply Inc.
See all →- HighBeak & Skiff Alcohol Antiseptic Sanitizer recalled for acetaldehyde contamination
FDA (Drugs) · 2026-09-09
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- ModeratePrimidone Tablets Recalled Due to API Cross-Contamination
FDA (Drugs) · 2026-05-27
Same hazard · nitrosamine impurity
See all →- HighEnovachem duloxetine capsules exceed the nitrosamine acceptable intake limit
FDA (Drugs) · 2026-06-10
- HighCipla cinacalcet 60 mg tablets exceed the nitrosamine daily intake limit
FDA (Drugs) · 2026-04-22
- HighCipla cinacalcet 30 mg tablets exceed the nitrosamine daily intake limit
FDA (Drugs) · 2026-04-22
- HighCipla cinacalcet 90 mg tablets exceed the nitrosamine daily intake limit
FDA (Drugs) · 2026-04-22
- HighPrazosin hydrochloride 100-count bottles recalled over nitrosamine impurity
FDA (Drugs) · 2026-04-08